title: Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma.
abstract: Neuroblastoma is the most common extracranial solid tumor of childhood, and iodine-131-metaiodobenzylguanidine (MIBG) therapy is a new approach for grade IV neuroblastoma. We describe the case history of a 3-year-old girl with recurrent neuroblastoma who received MIBG therapy with reduced-intensity allogeneic stem cell transplantation (RIST) because of an extensive bone marrow involvement. The post-transplant course was uneventful and complete chimerism was obtained. Neither acute nor chronic graft-versus-host disease (GVHD) was observed. The patient remained in remission for 3 months after RIST until the second relapse. MIBG therapy combined with RIST warrants further trials.
authors.affiliation: Department of Pediatrics, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan.
authors.forename: Hiroka
authors.initials: H
authors.lastname: Takahashi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Manabe
authors.forename: Chiaki
authors.initials: C
authors.lastname: Aoyama
authors.forename: Takahiro
authors.initials: T
authors.lastname: Kamiya
authors.forename: Itaru
authors.initials: I
authors.lastname: Kato
authors.forename: Ayako
authors.initials: A
authors.lastname: Takusagawa
authors.forename: Chitose
authors.initials: C
authors.lastname: Ogawa
authors.forename: Miwa
authors.initials: M
authors.lastname: Ozawa
authors.forename: Ryota
authors.initials: R
authors.lastname: Hosoya
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Yokoyama
mesh_terms: D019797:3-Iodobenzylguanidine / Q000627:therapeutic use*; D000310:Adrenal Gland Neoplasms / Q000601:surgery*; D000315:Adrenalectomy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005047:Etoposide / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D000077146:Irinotecan; D009447:Neuroblastoma / Q000188:drug therapy / Q000532:radiotherapy* / Q000556:secondary* / Q000601:surgery; D012008:Recurrence; D016879:Salvage Therapy; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D007457:Iodine Radioisotopes; D019797:3-Iodobenzylguanidine; D014750:Vincristine; D005047:Etoposide; D000077146:Irinotecan; D004317:Doxorubicin; D003520:Cyclophosphamide; C027260:pirarubicin; D002945:Cisplatin; D002166:Camptothecin